Search Results - "Phatak, Hemant"

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban by Tepper, Ping G, Mardekian, Jack, Masseria, Cristina, Phatak, Hemant, Kamble, Shital, Abdulsattar, Younos, Petkun, William, Lip, Gregory Y H

“…Limited real-world data are available regarding the comparative safety of non-vitamin K antagonist oral anticoagulants (NOACs). The objective of this…”
Get full text

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States by Lip, Gregory Y H, Pan, Xianying, Kamble, Shital, Kawabata, Hugh, Mardekian, Jack, Masseria, Cristina, Bruno, Amanda, Phatak, Hemant

“…Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs). To compare the major bleeding risk among newly…”
Get more information

Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban by Lip, Gregory Y H, Pan, Xianying, Kamble, Shital, Kawabata, Hugh, Mardekian, Jack, Masseria, Cristina, Phatak, Hemant

“…Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) patients to an increased risk of stroke. This study describes the…”
Get full text

Relationships Between Beliefs about Medications and Nonadherence to Prescribed Chronic Medications by Phatak, Hemant M, Thomas, Joseph, III

“…Background: Medication beliefs of patients with a specific medical condition have been associated with nonadherence to drugs used to treat that condition…”
Get full text

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation by Lip, Gregory Y.H, Kongnakorn, Thitima, Phatak, Hemant, Kuznik, Andreas, Lanitis, Tereza, Liu, Larry Z, Iloeje, Uchenna, Hernandez, Luis, Dorian, Paul

“…Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral…”
Get full text

Quality of life, activity impairment, and healthcare resource utilization associated with atrial fibrillation in the US National Health and Wellness Survey by Goren, Amir, Liu, Xianchen, Gupta, Shaloo, Simon, Teresa A, Phatak, Hemant

“…This study builds upon current studies of atrial fibrillation (AF) and health outcomes by examining more comprehensively the humanistic burden of illness…”
Get full text

Travel burden associated with rare cancers: The example of Merkel cell carcinoma by Jain, Rahul, Menzin, Joseph, Lachance, Kristina, McBee, Patrick, Phatak, Hemant, Nghiem, Paul T.

“…Background There are limited data on the travel burden for cancer patients with rare tumor types, such as Merkel cell carcinoma (MCC). Objective The objective…”
Get full text

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial by Liu, Xianchen, Johnson, Margot, Mardekian, Jack, Phatak, Hemant, Thompson, John, Cohen, Alexander T

“…In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to…”
Get full text

Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan by Kamae, Isao, MD, PhD, Hashimoto, Yoichiro, MD, Koretsune, Yukihiro, MD, PhD, Tanahashi, Norio, MD, Murata, Tatsunori, MS, Phatak, Hemant, PhD, Liu, Larry Z., MD, PhD, Tang, Ann C., PhD, Feng Wang, Peter, MD, PhD, Okumura, Ken, MD, PhD

“…Abstract Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared with to warfarin, current standard of care, for stroke…”
Get full text

Long-Term Outcomes of Medicare Beneficiaries With Worsening Renal Function During Hospitalization for Heart Failure by Kociol, Robb D., MD, Greiner, Melissa A., MS, Hammill, Bradley G., MS, Phatak, Hemant, PhD, Fonarow, Gregg C., MD, Curtis, Lesley H., PhD, Hernandez, Adrian F., MD, MHS

“…We examined whether worsening renal function (RF) was associated with long-term mortality, readmission, and inpatient costs in Medicare beneficiaries…”
Get full text

Relation of Worsened Renal Function During Hospitalization for Heart Failure to Long-Term Outcomes and Rehospitalization by Lanfear, David E., MD, MS, Peterson, Edward L., PhD, Campbell, Janis, RN, Phatak, Hemant, PhD, Wu, David, PhD, Wells, Karen, BS, Spertus, John A., MD, MPH, Williams, L. Keoki, MD, MPH

“…Worsened renal function (WRF) during heart failure (HF) hospitalization is associated with in-hospital mortality, but there are limited data regarding its…”
Get full text

Real‐world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States by Pizzicato, Lia N., Nadipelli, Vijay R., Governor, Samuel, Mao, Jianbin, Lanes, Stephan, Butler, John, Pepe, Rebecca S., Phatak, Hemant, El‐Kersh, Karim

“…Treatment for pulmonary arterial hypertension (PAH) has evolved over the past decade, including approval of new medications and growing evidence to support…”
Get full text

Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation by Lip, Gregory Y.H., MD, Lanitis, Tereza, MSc, Kongnakorn, Thitima, PhD, Phatak, Hemant, PhD, Chalkiadaki, Corina, MSc, Liu, Xianchen, MD, PhD, Kuznik, Andreas, PhD, Lawrence, Jack, PhD, Dorian, Paul, MD

“…Abstract Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg BID versus high- and low-dose edoxaban (60 mg and 30 mg…”
Get full text

Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure by Patel, Uptal D., MD, Greiner, Melissa A., MS, Fonarow, Gregg C., MD, Phatak, Hemant, PhD, Hernandez, Adrian F., MD, MHS, Curtis, Lesley H., PhD

“…Background Kidney disease is common among patients with heart failure, but relationships between worsening renal function (WRF) and outcomes after…”
Get full text

RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers by Crijns, Harry J G M, Bash, Lori D, Chazelle, François, Le Heuzey, Jean-Yves, Lewalter, Thorsten, Lip, Gregory Y H, Maggioni, Aldo P, Martín, Alfonso, Ponikowski, Piotr, Rosenqvist, Mårten, Sanders, Prashanthan, Scanavacca, Mauricio, Bernhardt, Alexandra A, Unniachan, Sreevalsa, Phatak, Hemant M, Gitt, Anselm K

“…Atrial fibrillation is a serious public health problem posing a considerable burden to not only patients, but the healthcare environment due to high rates of…”
Get full text

Cost of venous thromboembolism in hospitalized medically ill patients by PENDERGRAFT, TRUDY, ATWOOD, MARK, LIU, XIANCHEN, PHATAK, HEMANT, LIU, LARRY Z., OSTER, GERRY

“…PURPOSEThe results of a study to estimate the economic costs of venous thromboembolism (VTE) in hospitalized nonsurgical patients during initial admissions and…”
Get full text

Impact of Worsening Renal Function During Hospital Admission on Resource Utilization in Patients With Heart Failure by Herout, Peter M., PharmD, Harshaw, Qing, MD, PhD, Phatak, Hemant, PhD, Saka, Gorkem, PhD, McNeill, Annie, PhD, Wu, David, PhD, Sazonov, Vasilisa, PhD, DeSagun, Robert, MPH, Shirani, Jamshid, MD

“…Renal impairment frequently accompanies heart failure (HF) and is a recognized independent risk factor for morbidity and mortality. Few data are available…”
Get full text

Venous thromboembolism prophylaxis and clinical consequences in medically ill patients by Baser, Onur, Liu, Xianchen, Phatak, Hemant, Wang, Li, Mardekian, Jack, Kawabata, Hugh, Petersel, Danielle, Hamilton, Melissa, Ramacciotti, Eduardo

“…The objective of this study was to examine venous thromboembolism (VTE) prophylaxis use, risk reduction, and readmission in medically ill patients during…”
Get full text

Use of the UKPDS Outcomes Model to predict all-cause mortality in U.S. adults with type 2 diabetes mellitus: Comparison of predicted versus observed mortality by Song, May, Alexander, Charles M, Mavros, Panagiotis, Lopez, Victor A, Malik, Shaista, Phatak, Hemant M, Wong, Nathan D

“…Abstract Aims The applicability of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model is unknown in populations with type 2 diabetes mellitus…”
Get full text

Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary by Jermendy, György, Erdesz, Diana, Nagy, Laszlo, Yin, Don, Phatak, Hemant, Karve, Sudeep, Engel, Samuel, Balkrishnan, Rajesh

“…The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian…”
Get full text